Cover Image

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenge...

Full description

Saved in:
Bibliographic Details
Main Authors: Gagelmann, Nico (Author) , Sureda, Anna (Author) , Montoto, Silvia (Author) , Murray, John (Author) , Bolaños, Natacha (Author) , Kenyon, Michelle (Author) , Beksac, Meral (Author) , Schönland, Stefan (Author) , Hayden, Patrick (Author) , Scheurer, Hans (Author) , Morgan, Kate (Author) , Garderet, Laurent (Author) , McLornan, Donal P (Author) , Ruggeri, Annalisa (Author)
Format: Article (Journal)
Language:English
Published: 26 September 2022
In: The lancet. Haematology
Year: 2022, Volume: 9, Issue: 10, Pages: e786-e795
ISSN:2352-3026
DOI:10.1016/S2352-3026(22)00226-5
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S2352-3026(22)00226-5
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2352302622002265
Get full text
Author Notes:Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P McLornan, Annalisa Ruggeri
Description
Summary:Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care—a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma.
Item Description:Gesehen am 31.01.2023
Physical Description:Online Resource
ISSN:2352-3026
DOI:10.1016/S2352-3026(22)00226-5

Similar Items